Medifast Past Earnings Performance
Past criteria checks 0/6
Medifast's earnings have been declining at an average annual rate of -3.2%, while the Personal Products industry saw earnings growing at 9.3% annually. Revenues have been growing at an average rate of 5.3% per year. Medifast's return on equity is 3.5%, and it has net margins of 1.1%.
Key information
-3.2%
Earnings growth rate
-1.7%
EPS growth rate
Personal Products Industry Growth | 20.9% |
Revenue growth rate | 5.3% |
Return on equity | 3.5% |
Net Margin | 1.1% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Nov 06Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Sep 03Medifast Business Continues To Shrink, Stock Still Risky
Aug 27Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Jun 26Medifast: Significant Undervaluation Even As Struggles Persist
May 24At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
May 24Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
May 24Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
May 06The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
May 01Medifast: Cheap Valuation, Uncertain Future
Mar 20Medifast Is Getting Attractive
Mar 07Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Feb 22Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Jan 20Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Dec 09Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Nov 24Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Nov 21Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Nov 09Medifast: The Race To Weight-Loss Drugs Not Lost Yet
Oct 09Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Aug 04Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?
Jul 26In The Murky MLM Space, Medifast Might Actually Hold Some Promise
Jul 21Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Jul 05Medifast: In Survival Mode Against Diet Pills And The Recession
Jun 14Medifast Holds Value During Headwinds
May 28Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M
Feb 21Medifast: A Low Earnings Multiple Despite Strong Financial Performance
Feb 07At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Jan 19Medifast declares $1.64 dividend
Dec 08A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Dec 01Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 10One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates
Nov 08Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy
Nov 06What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Oct 20We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt
Sep 18Medifast declares $1.64 dividend
Sep 08Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?
Sep 02Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good
Aug 21Revenue & Expenses Breakdown
How Medifast makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 674 | 7 | 470 | 5 |
30 Jun 24 | 770 | 29 | 531 | 5 |
31 Mar 24 | 898 | 68 | 570 | 5 |
31 Dec 23 | 1,072 | 99 | 645 | 5 |
30 Sep 23 | 1,218 | 120 | 713 | 5 |
30 Jun 23 | 1,373 | 133 | 796 | 4 |
31 Mar 23 | 1,530 | 142 | 897 | 5 |
31 Dec 22 | 1,599 | 144 | 951 | 5 |
30 Sep 22 | 1,639 | 151 | 982 | 4 |
30 Jun 22 | 1,662 | 157 | 999 | 4 |
31 Mar 22 | 1,603 | 165 | 959 | 4 |
31 Dec 21 | 1,526 | 164 | 907 | 4 |
30 Sep 21 | 1,413 | 158 | 837 | 4 |
30 Jun 21 | 1,271 | 150 | 745 | 4 |
31 Mar 21 | 1,097 | 125 | 644 | 3 |
31 Dec 20 | 935 | 103 | 561 | 3 |
30 Sep 20 | 841 | 95 | 509 | 3 |
30 Jun 20 | 759 | 76 | 472 | 3 |
31 Mar 20 | 726 | 76 | 455 | 3 |
31 Dec 19 | 714 | 78 | 443 | 3 |
30 Sep 19 | 689 | 74 | 423 | 2 |
30 Jun 19 | 638 | 72 | 390 | 2 |
31 Mar 19 | 568 | 64 | 349 | 2 |
31 Dec 18 | 501 | 56 | 309 | 2 |
30 Sep 18 | 433 | 47 | 269 | 2 |
30 Jun 18 | 371 | 40 | 228 | 2 |
31 Mar 18 | 330 | 34 | 202 | 2 |
31 Dec 17 | 302 | 28 | 188 | 0 |
30 Sep 17 | 286 | 25 | 177 | 2 |
30 Jun 17 | 277 | 24 | 173 | 2 |
31 Mar 17 | 273 | 20 | 168 | 2 |
31 Dec 16 | 275 | 18 | 170 | 2 |
30 Sep 16 | 273 | 18 | 167 | 3 |
30 Jun 16 | 271 | 17 | 166 | 3 |
31 Mar 16 | 272 | 19 | 169 | 2 |
31 Dec 15 | 273 | 20 | 169 | 2 |
30 Sep 15 | 274 | 18 | 167 | 0 |
30 Jun 15 | 277 | 18 | 170 | 0 |
31 Mar 15 | 279 | 19 | 171 | 0 |
31 Dec 14 | 285 | 21 | 173 | 1 |
30 Sep 14 | 267 | 27 | 157 | 0 |
30 Jun 14 | 285 | 27 | 170 | 0 |
31 Mar 14 | 307 | 28 | 187 | 0 |
31 Dec 13 | 324 | 27 | 202 | 0 |
Quality Earnings: MED has a large one-off loss of $12.5M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: MED's current net profit margins (1.1%) are lower than last year (9.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MED's earnings have declined by 3.2% per year over the past 5 years.
Accelerating Growth: MED's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MED had negative earnings growth (-93.9%) over the past year, making it difficult to compare to the Personal Products industry average (-5.2%).
Return on Equity
High ROE: MED's Return on Equity (3.5%) is considered low.